- Home
- AU vs TFX Comparison
AU vs TFX Comparison
Compare AU & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | TFX |
|---|---|---|
| Founded | 1944 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 5.4B |
| IPO Year | 1972 | N/A |
Fundamental Metrics
Financial Performance| Metric | AU | TFX |
|---|---|---|
| Price | $92.22 | $126.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | $82.67 | ★ $139.88 |
| AVG Volume (30 Days) | ★ 2.4M | 732.5K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.09% | 1.09% |
| EPS Growth | ★ 237.48 | N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $8,575,000,000.00 | $3,189,988,000.00 |
| Revenue This Year | $71.69 | $9.90 |
| Revenue Next Year | $14.39 | $10.51 |
| P/E Ratio | $20.69 | ★ N/A |
| Revenue Growth | ★ 61.82 | 5.42 |
| 52 Week Low | $23.53 | $102.58 |
| 52 Week High | $93.85 | $185.94 |
Technical Indicators
Market Signals| Indicator | AU | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 61.67 |
| Support Level | $82.94 | $120.31 |
| Resistance Level | $93.85 | $127.49 |
| Average True Range (ATR) | 2.68 | 2.95 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 87.72 | 86.46 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.